From the makers of
Track & Manage All Of Your Investments
Try It Now!
New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
NuVasive (NUVA)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Topic Listing for NuVasive
Ability
Ability Protect Intellectual Property Proprietary Technology Through Patents
Accounting Certain Investments Debt Equity Securities
Accounting Equity Instruments Issued Other Employees Acquiring Conjunction
Accounting Impairment Disposal Long-lived Assets
Accounting Income Taxes
Accounting Stock Appreciation Rights Other Variable Option Award
Accounting Stock Issued Employees
Accounting Stock-based Compensation
Accounting Stock-based Compensation-transition Disclosure
Accounting Treatment
Accounts Payable Accrued Liabilities
Accounts Receivable Related Valuation Account
Achievement Certain Milestones Related Acquisitions Required Make Payments
Acquisitions Unsuccessful Business Harmed
Additional Agreements
Adjustments Changes Capitalization Merger Change Control
Administration
Adverse Changes Reimbursement Procedures Payors Impact Ability Market
After Relocate New Headquarters Not Able Sublease Current
Aggregated Option Exercises 2004 Year-end Values
Agreed Parties After Effective Date Provided 127
Agreement
Agrees Provide Nuvasive Copy Certificate Insurance Request Advanced
Alexis Lukianov
Allograft Implants Technologies Become Subject Significantly Greater Regulation
Allowance Doubtful Accounts
Always Incurred Losses Significant Total Operating Since Inception
Amendment Termination 2004 Plan
Analyze Phase
Anti-takeover Provisions Organizational Documents Delaware Law Discourage Prevent
Asset Purchase Agreement
Assignment Intellectual Property Rights
Aster Echnology Ervices Greement
Authority
Authorization
Automatic Annual Increase Share Reserve
Background
Basis Presentation
Basis Presentation Principles Consolidation
Because Allograft Implants Entail Risk Injury Human Recipients
Because Significant Stock Ownership Executive Officers Directors Principal
Become Involved Securities Class Action Litigation Divert Managements
Become Subject Product Liability Claims Required Pay Damages
Beneficial Ownership Reporting Compliance
Binding Obligation Btc Enforceable Against Accordance Terms Except
Board Approval
Board Committees
Board Directors
Board Independence
Board Meetings Committees
Bonus Awards
Bonus Plan
Booth 203
Btc Report Writing Form Supplied Nuvasive Root Causes
Btcs Confidential Information
Build Phase
Business Combination
Business Combination Asset Acquisitions
Business Combinations Asset Acquisitions
Buyer
Buyers Conditions Closing
Cash Awards
Cash Compensation
Cash Equivalents Short-term Investments
Certain Relationships Related Transactions
Certification Chief Executive Officer Pursuant 302 Sarbanes-oxley Act
Certification Chief Financial Officer Pursuant 302 Sarbanes-oxley Act
Certifications
Certifications Chief Executive Officer Financial Pursuant Usc 1350
Changes Capitalization
Charter
Chief Executive Officer Compensation
Choose Acquire New Complementary Businesses Products Technologies Instead
Claims Relating Improper Handling Storage Disposal Biological Hazardous
Claims Relating Making Improper Payments Physicians Consulting Services
Classic Fusion
Clearance Pathway
Clinical Advisory Board
Clinical Trials
Clinical Trials Current Future Product Candidates Not Produce
Closing
Closing Buyer Shall Deliver Seller Each Following
Closing Seller Shall Deliver Buyer Each Following
Code Ethics
Commercially Successful Convince Spine Surgeons Products Attractive Alternative
Common Stock
Common Stock Market Price
Common Stock Par Value 0001 Per Share
Common Stock Reserved Future Issuance
Communications Directors
Comparison Cumulative Total Return Among Nuvasive Inc Nasdaq
Compensation Committee Interlocks Insider Participation
Compensation Committee Report Executive
Compensation Program Process
Competition
Compliance
Components Compensation
Composition
Comprehensive Income
Comprehensive Loss
Concentration Credit Risk Significant Customers
Conference Call
Confidentiality Intellectual Property
Consents
Consolidated Statements Operations
Continue Incur Increased Costs Result Recently Enacted Proposed
Continue Introduce New Creative Products
Contractual Obligations Commitments
Controls Procedures
Convertible Preferred Stock
Corporate Governance
Corporate Information
Cost Goods Sold
Critical Accounting Policies
Current Treatments Spine Disorders
Currently Involved Patent Litigation Action Involving Medtronic Not
Deductibility Executive Compensation
Deferred Stock-based Compensation
Delivery Title
Demand Minimally Invasive Alternatives
Departure Directors Principal Officers Election Appointment
Depend Clinical Investigators Sites Enroll Patients Trials Other
Depend Limited Number Sources Human Tissue Allograft Implants
Dependent Senior Management Team Key Clinical Advisors Scientific
Dependent Services Alexis Lukianov Keith Valentine Loss Either
Dependent Single Source Suppliers Manufacturers Certain Devices Components
Dependent Single Source Suppliers Manufacturers Certain Products Components
Deploy Phase
Description Business
Determining Executive Compensation
Development Projects
Device Manufacture
Device Specification Forms
Director Compensation
Director Fee Option Grants
Director Nomination
Director Nominations
Director Summary Compensation Table
Disclosure Regarding Forward-looking Statements
Disclosures Segments Enterprise Related Information
Distribution Stock Btc Shall Fifo Out Inventory Procedures
Dividend Policy
Documents Incorporated Reference
Early Termination Agreement Terminated Otherwise Provided Follows
Eileen
Elements Executive Compensation Program
Eligibility
Employee Retirement Plan
Employees
Employment Agreements
Employment Agreements Potential Payments Termination Change Control
Employment Change Control Agreements
Encounter Difficulties Integrating Acquired Products Technologies Businesses Adversely
Enforcement
Entire Agreement Amendment
Entry Material Definitive Agreement
Entry Material Definitive Agreement 201 Completion Acquisition
Equity Compensation
Equity Compensation Plan Information
Estimates
Exact Name Registrant Specified Charter
Except Share Per Data
Excess Obsolete Inventory
Executing Lock-up Letter Agreement
Execution Delivery Agreements
Executive Compensation
Executive Officers
Executive Officers Significant Employees
Exercise Option Form Consideration
Exercise Price
Exhibits
Exhibits Each Agreement Shall Considered Part Hereof Set
Expand Sales Marketing Efforts
Expect Price Common Stock Fluctuate Substantially Potentially Adversely
Fail Obtain Experience Significant Delays Obtaining Fda Clearances
Fail Properly Manage Anticipated Growth Business Suffer
Failure Build Effective Dedicated Distribution Network Products Significantly
Failure Continue Building Effective Exclusive Distribution Network Products
Failure Efforts Successfully Generate Business Hospitals Following Surgeon
Failure Efforts Train Spine Surgeons Significantly Reduce Market
Fair Value Financial Instruments
Favorable Demographics
Fdas Premarket Clearance Approval Requirements
Federal Income Tax Consequences Awards
Financial Statements Exhibits
Forecast Inventory
Forgiveness Loans Executive Officers
Form 10-k
Form 10-k 2006
Form 10-k 2007
Form 10-k 2008
Form 10-q
Former Name Address Changed Since Last Report
Forward-looking Statements Prove Inaccurate
Future Capital Needs Uncertain Need Raise Additional Funds
Future Sales Common Stock Depress Price
Future Success Depends Ability Timely Develop Introduce New
Future Success Depends Ability Timely Introduce New Products
General
General Administrative
General Philosophy Objectives
General Provisions
Governing Law Venue
Gratia
Gross Margin
Gross Profit
Guidance
Hansen Yuan
Healthcare Fraud Abuse
Highlights
Highly Competitive Market Segment Face Competition Large Well-established
Hospitals Unable Obtain Sufficient Reimbursement Procedures Performed Products
Human Cell Tissue Cellular Based Products
Important Notice Regarding Availability Proxy Materials Stockholder Meeting
In-process Research Development
Increased Implants
Indemnification
Indemnification Agreements
Indemnification Buyer
Indemnification Certain Directors Executive Officers
Index
Index Consolidated Financial Statements
Industry Background Market
Information Required Set Forth Proxy Statement Incorporated Report
Initial Sale Time
Inspection Records
Insurance
Insurance Notice Claims
Intellectual Property
Intellectual Property Purchase Agreement
Intellectual Property Purchase Agreement Addendum
Interest Other Expense Net
Interest Other Income Expense Net
Interest Other Income Net
International
Inventories
Inventory
Issuances Options
Jack Blair
James Blair Phd
Labeling Ifu Specifications Sample Labels
Legal Proceedings
Lesley Howe
Limited Operating History Incurred Significant Losses Since Inception
Limited Sales Marketing Experience Efforts Largely Dependent Parties
Liquidity Capital Resources
Loaner Equipment
Loaners
Lock-up Letter Agreement
Maintain Phase
Manufacturing Process Records
Manufacturing Supply
Market Opportunity
Marketing Costs
Mas
Mas Biologics
Mas Maxcess
Mas Neurovision
Mas Platform
Mas Platform Expansion
Mas Revenue
Mas Specialized Implants
Mas-maxcess
Mas-neurovision
Mas-specialized Implants
Master Technology Services Agreement
Master Technology Services Agreement Amendment
Maximizes Access
Maximum Access Surgery Mas
Medical Device Industry Characterized Patent Litigation Become Subject
Medidata Services
Meetings
Membership
Merger Change Control
Milestone Payment
Minimally Invasive Surgical Procedures
Mix Compensation
Modifications Marketed Products Require New 510 Clearances Premarket
Motion Preservation-total Disc Replacement Products
Net Loss Per Share
New Products
Nominees Continuing Directors
Non-discretionary Grants Outside Directors
Non-gaap Information
Nontransferability Awards
Not Able Sublease Former Headquarters Receive Rental Income
Not Able Timely Develop New Products Product Enhancements
Not Applicable
Not Intend Pay Cash Dividends
Notes Payable
Notice Annual Meeting Stockholders
Notices
Now Therefore
Number 000-50744
Nuvasive
Nuvasive Completes Follow-on Public Offering
Nuvasive Inc
Nuvasive Reconfirms 2005 Full Revenue Guidance
Nuvasive Solution Maximum Access Surgery Mas
Nuvasives Confidential Information
Nuvasives Representations Warranties Covenants
Operating Expenses
Option Exercises
Option Exercises Stock Vested
Options Granted Last
Other Agreements
Other Information
Other Matters
Other Responsibilities
Outstanding Securities Quorum
Oversight Financial Reporting Other Disclosure
Oversight Independent Auditor
Overview
Overview Compensation Philosophy Program
Ownership Intellectual Property Rights
Packing Labeling Ifu Specifications
Part
Part Incorporates Information Reference Definitive Proxy Statement Annual
Part Other Information
Party Intellectual Property Payments
Patent Costs
Patents
Payments Nuvasive Shall Promptly Pay Tissues Shipped Per
Pcd 15145
Performance Graph
Perquisites Other Benefits
Pervasive Continuing Fda Regulation
Peter Farrell Phd
Policy Regarding Related Party Transactions
Power Attorney
Premarket Approval Pathway
Press Release
Price Evaluated Adjusted Necessary Each Least Before Anniversary
Pricing Pressure Competitors Sources Medical Reimbursement Impact Ability
Principal Accountant Fees Services
Proceeds
Processing Transfer Responsibilities Btc
Product Shipment Costs
Products Development
Products Development Motion Preservation
Professional Fees Purchase Orders Terms Payment
Properties
Property Equipment
Property Plant Equipment
Proposal Election Directors
Proposal Ratification Independent Registered Public Accounting Firm
Provide Assurance Regarding Independent Registered Public Accounting Firms
Provide Tailored Solutions Response Surgeon Needs
Provides Benefits Mas Broad Application
Proxy Voting
Purchase Sale Intellectual Property Rights
Purpose
Purpose Powers
Pursuant Underwriting Agreement
Quantitative Qualitative Disclosures Market Risk
Quarterly Financial Results Likely Fluctuate Significantly Because Sales
Quarterly Royalty Payments
Reasons Rsb Acquisition
Recent Accounting Pronouncements
Recent Changes Required Accounting Treatment Stock Options Had
Recent Changes Required Accounting Treatment Stock Options Material
Recent Financial Crisis General Slowdown Economy Adversely Affect
Recent Product Introductions
Recent Sales Unregistered Securities
Recitals
Reclassifications
Reduced Hospital Stays
Reduced Surgery Times
Related Party Transactions
Relationship William Blair Llc
Reliance Single Source Suppliers Limit Ability Meet Demand
Report Audit Committee
Report Compensation Committee
Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Internal Control
Reporting Comprehensive Income
Reports
Representations
Representations Warranties Buyer
Representations Warranties Covenants Seller
Required Vote
Research Development
Responsibilities
Results Operations
Results Operations Financial Condition
Revenue
Revenue Recognition
Revenues
Revocation Proxy
Risk Factors
Risks Related Financial Results Need Financing
Risks Related Intellectual Property Potential Litigation
Risks Related Securities Markets Ownership Common Stock
Robert Hunt
Safety Products Not Yet Supported Long-term Clinical Data
Sales Marketing
Sales Marketing Administrative
Sales Marketing Commercial Compliance
San Diego
San Diego 2005
Sarbanes-oxley Act 2002
Schedule
Schedule 14a
Schedule Flow-through Terms
Schedule Free Writing Prospectuses Included Disclosure Package
Schedule Hosting Services
Schedule Medidata Applications
Schedule Statement Work
Schedule Valuation Accounts
Secondary Offering
See
Selectively License Acquire Complementary Spine Products Technologies
Seller
Sellers Investor Representations
Severability
Severance Benefits
Severance Change Control Benefits
Share Based Payments
Share Reserve
Shareowners Employees
Short-term Investments
Signature Page Exclusive Manufacturing Agreement
Signatures
Sizes Augmentation Device
Solicitation Costs
Spine Anatomy Disorders
Spine Journal
Spine Surgeons Unable Obtain Sufficient Reimbursement Procedures Performed
Stablish Integrated Surgical Systems Standard Care
Sterilization Specifications
Stock Appreciation Rights
Stock Awards
Stock Based Compensation
Stock Options
Stock-based Compensation
Stockholder Proposals Annual Meeting Held 2007
Stockholder Proposals Annual Meeting Held 2008
Stockholders Sharing Same Address
Strategy
Study Protocol Phase Pivotal Cerpass
Subject Damages Resulting Claims Employees Wrongfully Used Disclosed
Subject Damages Resulting Claims Officers Employees Wrongfully Used
Subject Litigation Regarding Cadavers Purchased Originated University California
Subsequent Events
Successors Assigns
Summary Compensation Table
Summary Proposal
Supplemental Information
Suppliers Fail Comply Fdas Quality System Regulations Manufacture
Suppliers Subject Claims Non-compliance Fda Regulations Connection Processing
Supply Agreement
Surgeon Training Education
Table Contents
Tax Accounting Considerations
Taxing Authority Connection Judicial Administrative Proceedings Relating Liability
Technology
Term Option
Term Termination
Termination Awards
Test Phase
Third-party Reimbursement
Titanium Surgical Mesh System
Total Revenues
Trademarks
Triad Cervical Allograft System
Triad Lumbar Allograft Systems
Ucla Litigation
Uses Conventional Instruments
Vote Important
Warrants
Whereas
Witnesseth
Skip the spreadsheet. Track your investments automatically.
Start now